Dividend Kings and Aristocrats List: 10 Biggest Stocks

In this article, we will discuss 10 biggest dividend kings and dividend aristocrats. If you want to read our detailed analysis of dividend stocks and their returns in the past, go directly to read Dividend Kings and Aristocrats List: 50 Biggest Stocks. 

10. Abbott Laboratories (NYSE:ABT)

Market Cap as of January 28: $191.7 billion 

Abbott Laboratories (NYSE:ABT) is an American multinational medical device and healthcare company that offers innovative health solutions for its patients. In January, Barclays raised its price target on the stock to $125 with an Overweight rating on the shares, appreciating the company’s sequential improvements in medical device growth.

On December 9, Abbott Laboratories (NYSE:ABT) declared an 8.5% hike in its quarterly dividend to $0.51 per share. This was the company’s 51st consecutive year of dividend growth, which makes it one of the best dividend stocks on our list. The stock’s dividend yield on January 28 came in at 1.86%.

At the end of September, 62 hedge funds tracked by Insider Monkey reported having stakes in Abbott Laboratories (NYSE:ABT), up from 61 in the previous quarter. The collective value of these stakes is over $3 billion. With over 9 million shares, Fisher Asset Management was the company’s leading stakeholder in Q3.

Stewart Asset Management mentioned Abbott Laboratories (NYSE:ABT) in its Q3 2022 investor letter. Here is what the firm has to say:

“We also need to point out one global consequence of the rapid rise in interest rates: an irrepressibly strong dollar. This hurts the reported earnings of U.S. companies who sell their goods and services overseas. Foreign currency earnings translate into fewer dollars and thus lower earnings. Most of the companies in your portfolios gain a notable amount of earnings from their international operations. While the strength or weakness of a currency doesn’t change the quality of a business or its longer-term earnings power, it can change the reported earnings of a company over short periods of time. It is difficult to forecast this effect accurately because many of our companies manufacture where they sell, which to some extent dulls the sharp negative effect of a surging dollar. Abbott (NYSE:ABT), among others, is a good example.”